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Summary 
A radioimmunoassay for the measurement of rat pancreatic polypeptide (RPP) in 
serum or plasma has been developed and characterized using a new guinea-pig 
anti-rat-PP antibody. The assay provides a high degree of sensitivity and lacks cross- 
reactivity (CR < 0.01 ~o) to neuropeptide Y and peptide YY. It also does not interact 
with PPs of other species or peptide hormones namely, amylin, glucagon, human insulin, 
human-PP, human-proinsulin, rat C-peptide and rat insulin. The assay employs yn- 
thetic rat PP as standards from concentrations of 21-2100 pg/ml (i.e., 5-500 pM) and 
produces a sensitivity limit of 19 pg/ml (4.5 pM) PP at + 3 S.D. The intra- and inter- 
assay ~o coefficient of variations are 6.4~o and 5.9~o, respectively. The ~o recovery of 
RPP added to rat serum samples ranges from 98~o to 103~o. Assay of serum volumes 
ranging from 25/~1 to 100 #1 does not significantly alter the expected RPP level. The 
migration patterns of rat serum PP and that of a synthetic RPP are identical by 
Sephadex G-50 chromatographic analysis. The mean values of fasting and a 2 h 
post-feeding plasma RPP levels in normal rats are 40 + 2 and 80 + 10 pg/ml (9.5 pM 
and 19.0 pM), respectively. Rat-PP release during insulin induced hypoglycemia n
conscious rats rises from 38 + 5 pg/ml to 261 + 34 pg/ml (9.0 to 62.1 pM, P < 0.005) 
by 30 min. Additionally, the antibody used in this study cross-reacts well with mouse-PP 
as determined by linear serum dilution curves, thus making it useful in the measurement 
of murine-PP. 
In conclusion, we have developed and validated a sensitive and specific rat-PP assay. 
This assay provides anew tool for the reliable measurement of PP in physiologic studies 
using rat and mouse animal models. 
Correspondence: R.L. Gingerich, Department of Pediatrics, Box 8116, Washington University, St. Louis, 
MO 63110, U.S.A. 
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Introduction 
Pancreatic polypeptide (PP) is a hormone secreted by F-cells of pancreatic islets of 
Langerhans [ 1,2] with little inter-mammalian species variation in the primary structures 
[3-6]. The similarity in PP primary structure among most mammals has previously 
justified use of non-isologous antibodies (e.g., anti-human-PP) and bovine-PP tracer 
~25I(tyr°27) bPP~_36 in radioimmunoassays (RIA) to determine PP concentrations in 
tissue and plasma. Availability of RIA techniques for PP in human and other verte- 
brates has made possible studies which have uncovered physiologic roles for PP 
including, the inhibition of stimulated pancreatic exocrine secretion [ 5 ] and the augmen- 
tation of insulin inhibited hepatic glucose production [6-8]. These actions of PP are 
mediated by specific receptors which have been identified and characterized in various 
vertebrate tissue and plasma membranes [9-13]. Pancreatic polypeptide receptor 
studies and the recent novel findings that PP circulates in heterogeneous forms in human 
plasma [14] have rekindled interest in the physiologic role of this hormone. 
Levels of PP in human and many other vertebrates are readily determined by specific 
RIA techniques, however, there was previously no reliable radioimmunoassay for 
rat PP due largely to the high degree of heterology between rat PP and PPs of other 
mammalian species. This heterology occurs in a region of PP structure which results in 
very low crossreactivity with commonly employed antibodies to human or bovine PPs. 
A sensitive and specific rat-PP immunoassay capable of detecting minute concentra- 
tions in plasma is desirable since the rat is a widely used animal model for the studies 
of pancreatic islet secretory function. The present report describes and validates a 
specific radioimmunoassay for rat-PP which provides a high degree of sensitivity and 
specificity. The cross-reactivity of PPs of other vertebrate species (except mouse) and 
various other peptide hormones i negligible. This RIA will provide a reliable assay for 
PP levels in the rat and mouse plasma samples. 
Materials and Methods 
Materials 
Synthetic rat pancreatic polypeptide was obtained from Peninsula Laboratories, Inc. 
Guinea-pig anti-rat-PP serum (lot RPP64), goat anti-guinea-pig I G serum (GP020P) 
and normal guinea-pig carrier were obtained from Linco Research, Inc., 16217 
Westwoods Business Park, St. Louis, MO 63021, U.S.A. Other reagents, namely, 
buffer salts, EDTA, bovine serum albumin (BSA, radioimmunoassay grade), ethyl- 
mercurithiosalicylic a id (EMTSA) sodium salt, trasylol and leupeptin were purchased 
from Sigma Chemical Co., St. Louis, MO, U.S.A. 
Procedure 
(i) Rat serum preparation. Male Sprague-Dawley rats weighing 350-400 g (Wash- 
ington University Office of Laboratory Animal Care) were used in these studies. Sera 
were obtained from blood collected under light diethyl ether anesthesia via cardiac 
puncture and/or carotic arterial sampling catheter. Trasylol (1000 KIU/ml serum) was 
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added before storing serum at - 20 °C for later assay. All serum samples were assayed 
within 3 weeks of collection following a single freeze-thaw cycle. 
(ii) Rat-PP release during glycemic studies. (a) Insulin induced hypoglycemia. To 
validate the applicability of our rat-PP assay in an experimental situation, hypoglycemia 
was induced in fasted (conscious) male Sprague-Dawley rats (350-400 g) by adminis- 
tering regular porcine insulin (1-2 units per kg body weight) i.v. through a jugular 
cannula. After an initial blood sample was drawn and placed in an EDTA tube to 
determine base line glucose level, blood samples for measurement of glucose and 
PP levels were drawn again 30 min after insulin injection. Plasma was separated for 
glucose and PP analyses. 
(b) Meal stimulated rat-PP release. In the experiments designed to measure fasting 
and postfeeding levels of rat serum PP, male rats (350-400 g) had carotid arterial 
sampling catheters (ID 0.016in, OD 0.029in, Teleflex, Inc., New York) implanted 
3 days prior to the study and were fasted overnight for 18 h. At 9 am, a blood sample 
(1 ml) was drawn and the animals were immediately fed (ad libitum) normal aboratory 
chow (Purina Feed Company). Blood samples were drawn again after 1, 2 and 4 h 
postfeeding. Plasmas were separated for glucose and PP analyses and was stored at 
- 20 °C until hormone analyses were completed. 
(iii) Radioiodination of rat-PP. Rat-PP was radiolabeled by a lactoperoxidase- 
hydrogen peroxide method [ 15]. The following reagents were added in the order listed 
at room temperature to the reaction vessel (glass culture tube 10 x 75 ram): rat-PP (5/~g 
in 200 #1 of 0.2 M phosphate buffer, pH 7.6), 30 #1 lactoperoxidase (145 ktg/ml), 30/~1 
of iodine-125 (carrier-free sodium salt; 3 mCi/30/A, Amersham Corporation). The 
reaction was initiated by two-interval dditions of 30 #1 of 0.015 ~o hydrogen peroxide. 
Each addition of hydrogen peroxide was followed by 5 min waiting interval. The 
reaction was stopped by adding 100 #1 of 7.5 M urea. Free iodine was removed by 
Sephadex G-50 column chromatography using phosphate 0.05 M with 0.1~o BSA, 
pH 7.6) as eluting buffer. Immunoreactive labeled rat-PP migrated as a single peak at 
approx. Kay ~ 0.7. Sufficient racer was diluted to 15,000 cpm/100/~1 to perform all 
assays anticipated over a 6-week period. The dilution factor was recorded for future 
reference and the 'assay-ready' tracer was kept frozen at - 20 °C until used. This tracer 
retained stable immunoreactivity for 8 weeks. 
(iv) Rat-PP radioimmunoassay. Assay set-up consisted of total radioactive tubes 
(TOTAL), non-specific binding tubes (N S B), rat-PP standards (range 21-2100 pg/ml), 
quality controls and unknowns. Phospho/saline buffer (0.05 M) was employed as assay 
buffer containing 0.025 M EDTA, 1000 KIU/ml trasylol, 25/~g/ml leupeptin and 1.0~o 
B SA (RIA grade) at pH 7.4. Assays were performed as follows: rat-PP standard (100/~1 
of 0, 21, 42, 84, 210, 420, 840, 2100 pg/ml) were pipetted in triplicate into borosilicate 
glass tube (12 x 75 mm). Quality controls (100/A) and unknowns (100 #1) were pipetted 
in duplicate. Assay buffer was added to NSB (300 ~1) and to the remainder of assay 
tubes (100 #1), except TOTAL. Rat-PP antiserum, diluted to obtain 35-45~o, B/B o 
binding, was pipetted into all tubes except TOTAL and NSB. The tubes were gently 
shaken, covered with aluminum foil and incubated 72 h at 4 ° C. 
After the first 72 h incubation, 125I-rat-PP tracer, diluted when freshly iodinated to 
obtain 15,000 cpm per 100/~1, was pipetted to all tubes. The tubes were again shaken, 
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covered and incubated for an additional 24 h at 4 °C. Radiolabeled rat-PP bound to 
antibody was separated from free ligand by second antibody precipitation during a 2 h 
incubation (4 ° C). Immediately prior to centrifugation, 1 ml assay buffer without B SA 
was added to all tubes except TOTAL tubes to reduce non-specific ounts associated 
with precipitate. The tubes, were shaken, centrifuged (3000 g) for 20 min at 4 ° C. The 
supernatant was decanted and the pellet counted in an automated gamma counter 
(Apex Automatic Gamma Counter, Micromedic Systems, Inc.). The calculations for 
each sample were performed by the automated gamma counter with a data reduction 
system using log/logit transformation. 
(v) Limits of test procedure. The assay was rejected if one reference quality control 
fell outside of two standard eviations of the mean obtained from 10 previous assays. 
Unknown rat-PP levels were reassayed if the difference between duplicates was > 10Yo 
coefficient of variation. Any PP value less than the lowest standard (21 pg/ml) when 
using 100 #1 sample was recorded as < 21 pg/ml and any value greater than the highest 
standard (2100 pg/ml)was diluted and reassayed. 
Results 
Assay performance characteristics-reference curve 
An assay standard curve for rat-PP (RPP) is presented in Fig. 1. Each point repre- 
sents mean + S.E. (n = 20) of percent binding of known RPP standard concentrations 
over zero binding (%B/Bo). The %B/B o observed for each standard was plotted on the 
ordinates against he log of concentration of standard on the abscissa. The EDso was 
290 + 9 pg/ml, while EDzo and EDso were 960 + 13 pg/ml and 88 + 3 pg/ml, respec- 
tively. Sensitivity limit ofrat-PP assay calculated at + 3 S.D. was 19 pg/ml. Sensitivity 
is defined as the smallest amount of unknown ligand that can be distinguished from no 
ligand. 
Preliminary data revealed a decrease in serum PP concentration following freezing 
and thawing of samples. This was attributed to degradation ofPP by serum proteinases. 
Since proteolytic degradation is generally considered to be a greater potential problem 
when using serum as compared to plasma samples, we used serum to test the protective 
property of various protease inhibitors. Leupeptin (25 #g/ml) and benzamidine 
(1 mg/mt) afforded 94 ~o and 87 ~o protection, respectively, when tested on the degrada- 
tion of rat-PP tracer in serum samples during 24 h incubation at 4 °C. The high 
concentration fbenzamidine (1 mg/ml, however, significantly decreased ~o bound over 
zero binding (B/Bo). Trasylol (1000 KIU per ml) was minimally effective while chloro- 
mercuriphenylsulfonic acid (PMCB 200 #g/ml), chymostatin (125/~g/ml) and trypsin 
inhibitor (625 #g/ml) were ineffective. Therefore, leupeptin (25 #g/ml) and trasylol 
(1000 KIU/ml) were added in all subsequent RPP assays to prevent proteolytic degrada- 
tion of PP. Leupeptin was also added to all serum or plasma samples anticipated for 
storage prior to assay. 
Intra-assay and between-assay variation 
Intra-assay variation is shown in Table Ia. Five rat serum samples spiked with 
63 
i-,- 
Z 
i,.u 
U 
u.i 
o.. 
100 
0% RPP(pg/ml) %B/B91 
21 95,,11 
90 ~N 42 90_.2 1 
~ . .  84 83+3 J 
I : )  210 60_+6 l 
- ~  420 40+4 I 
80 ~ 840 22_+2 J
12+l] 
7O 
o 
6O 
50 
40 
30 
2O 
I010 i , i 
1 O0 Io000 l 0,000 
RAT PANCREATIC POLYPEPTIDE 
(pg/rnl) 
Fig. 1. Rat-PP assay standard curve. Each point represents mean + S.E. (n = 20) of percent binding of 
known RPP standard concentrations over reference binding. EDso = 88 + 3 pg/ml, EDso = 290 + 9 pg/ml, 
ED2o = 962 + 13 pg/ml. Sensitivity limit at _+ 3 S.D. = 19 pg/ml. PP values on x-axis are expressed in log 
concentration. 
varying concentrations of RPP were assayed uplicate in 10 separate assays. Intra- 
assay variation of the five samples in 10 assays ranged from 5.9 to 9.4~o. Percent 
coefficient of variations (~/o CV) were within acceptable range regardless of the concen- 
tration of RPP in the serum sample. To determine variation between assays (Table Ib), 
four rat serum samples containing a wide range concentrations of RPP were assayed 
in 12 duplicate tubes in 10 separate assays. Between-assay ~o CV ranged between 2.7 % 
and 8.6~o with the expected higher %CV encountered at both ends of the standard 
curve.  
Spiking recovery of rat-PP and parallelism of serum dilution 
The recovery of RPP at different concentrations in serum is shown in Table IIa. 
Varying concentrations of RPP were added to five rat serum samples and the RPP level 
in each sample was measured in 20 separate assays. Recovery was similar whether high 
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TABLE I 
lntra-assay variation and between assay variation 
Intra-assay variation (a) 
(mean + S.D.) 
Between assay variation (b) 
(mean _+ S.D.) 
sample No. RPP (pg/ml) ~o C.V. sample No. RPP (pg/ml) ~o C.V. 
1 159 + 15 5.4 1 169 + 13 5.7 
2 286 +_ 19 3.0 2 276 + 7 2.7 
3 509 + 30 6.9 3 524 + 32 6.4 
4 986 + 79 8.0 4 1069 + 93 8.6 
5 1446 + 123 8.5 
Intra-assay variation (a) was performed in 10 duplicate tubes from five rat serum samples containing 
varying concentrations of RPP in ten separate assays. Mean + S.D. and ~o C.V. of ten observations are 
shown. Between assay variation (b) was determined in 12 duplicate tubes in 10 separate assays from 
four rat serum samples containing varying concentrations of rat-PP. Mean + S.D. of means and ~o C.V. 
are shown. 
TABLE II 
Spiking recovery of rat pancreatic polypcptide (a) and effect of serum dilution on rat pancreatic polypcptide 
assay (b) 
(a) Rat-PP added (pg/ml) Observed (pg/ml) Expected (pg/ml) Percent recovery 
(b) 
0 (basal) 47 + 6 - - 
84 128 + 14 131 + 9 98 + 5 
100 150 _+ 4 147 + 4 102 _+ 4 
210 262 + 11 257 + 8 102 + 6 
420 492 + 25 477 _+ 7 103 _+ 3 
840 899 _+ 24 882 + 40 102 + 8 
Serum dilution effect: 
serum volume 
100/~1 627 + 40 - - 
50#1 654 + 17 627 + 40 104 + 3 
25 #1 668 + 14 627 + 40 107 + 9 
(a) Varying concentrations of RPP were added to five rat serum samples and the RPP content was 
determined by RIA. Mean _+ S.D.M. of the observed concentrations for 20 separate assays are shown. 
~o recovery was calculated on the observed vs. expected. (b) Aliquots of pooled rat serum containing 
high RPP levels were added to assays in volumes indicated. Dilution factor of 1, 2 and 4 representing 
100 #1, 50/~l and 25 #1, respectively, were applied in calculating observed concentrations. 
Mean _+ S.D.M. of RPP concentration and ~ recovery for 20 separate assays are shown. 
(840 pg /ml )  o r  low (84 pg /ml )  concent ra t ions  o f  RPP  was  tes ted  ind icat ing  recovery  
e f f ic iency throughout  the  s tandard  curve  range.  Average  percent  recovery  range  f rom 
98~o to 103~o. 
E f fec t  o f  vary ing  serum vo lumes  (25 #1, 50 #l  and  100 #1) was  tes ted  in each  o f  
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20 separate assays to determine the effect of serum on the expected concentrations of
RPP, Table lib. The assay produced similar observed values and ~o recoveries regard- 
less of volume of serum in the assay. Hence, varying the volume of rat serum in the assay 
from 25 #1 to 100 #1 will produce no significant alteration of the observed RPP level. 
Spec city 
The specificity of rat-PP antibody used in this study was tested in assays designed 
to determine percent cross reactivity (CR) of the rat-PP antibody to other ligands likely 
to cocirculate with PP in blood under various experimental situations. As shown in 
Table III, amylin (100 ng/ml), glucagon (33 nM), human insulin (32 nM), human-PP 
(1.7nM), human proinsulin (1.7nM), neuropeptideY (430ng/ml), peptideYY 
(430 ng/ml), rat C-peptide (32 nM) and rat insulin (32 raM), respectively, did not 
produce measurable displacement of rat-PP tracer. 
Rat serum-PP migration of Sephadex chromatograph 
The authenticity of assay measurements a native PP was ascertained by column 
chromatography. 4 ml of rat serum was collected after insulin-induced hypoglycemia to
insure high levels of PP (255 pg/ml). The serum was lyophilized, reconstituted with 
1.5 ml of water and applied to a Sephadex G50 column (0.9 × 55 cm, 1.2 ml/fraction) 
using phospho/saline (0.05 M, plus 1~o BSA, pH 7.4) as eluting buffer. Rat-PP was 
measured in each column fraction and plotted in Fig. 2. The migration pattern of rat 
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Fig. 2. A representative rat serum PP migration i a Sephadex G-50 column. Arrows indicate migration 
patterns of void volume, synthetic RPP standard and column volume, respectively. RPP was eluted with 
0.05 M PO 4 plus 1% BSA. 
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TABLE III 
Percent cross-reactivity of rat pancreatic polypeptide antibody to various peptide hormones 
Test hormone Concentration tested ~o Cross-reactivity 
Rat-PP 5-500 PM 100~o 
Mouse-PP mouse-serum 100~o by linear dilution curve 
Amylin 100 ng/ml no displacement 
Glucagon 33 nM no displacement 
Human-pp 1.7 nM no displacement 
Human insulin 32 mM no displacement 
Human proinsulin 170 nM no displacement 
Neuropeptide Y 430 ng/ml no displacement 
Peptide YY 430 mg/ml no displacement 
Rat C-peptide 32 nM no displacement 
Rat insulin 32 mM no displacement 
Percent cross-reactivity of rat-PP antibody was determined for various peptide hormones. The concen- 
tration of test hormone required to displace 50~o of labeled rat-PP from rat-PP antibody (EDso) was 
used to determine cross-reactivity as described under Materials and Methods. Cross-reaetivities were 
consistently ess than 0.01~o. 
serum PP was identical to that of synthetic rat PP, val idating the serum measurement  
as authentic rat PP. 
Rat-PP level in typical glycemic stud), 
To validate the applicabil ity of tliis assay, rat -PP levels were measured following 
fasting, post-feeding and during insul in induced hypoglycemia. Table IV shows fasting 
p lasma glucose, post-feeding lycemic levels and the corresponding p lasma PP levels. 
P lasma PP level was increased 2-fold from 40 + 2 to 80 + 10 pg/ml by 2 h after the 
animals were allowed free access to food. The increase was correspondent  to the 
elevation in p lasma glucose during same period (109 + 2 vs. 146 + 5 mg/dl). G lucose 
and PP levels in p lasma fell slightly 4 h later, apparently reflecting decreased feeding 
drive since the experiments were by design conducted ur ing the day (see Materials and 
Methods,  ii) when feeding activity is known to be decreased in rats. Rat -PP  release 
TABLE IV 
Fasting and post-feeding plasma concentrations of rat pancreatic polypeptide 
Condition Glucose (mg/dl) PP (pg/ml) 
Fasting 109 + 2 40 + 2 
2 h post-feeding 146 _+ 5 80 + 10 
4 h post-feeding 135 + 4 44 + 9 
Fasting and post-feeding plasma concentrations of rat PP. Plasma glucose level and PP concentrations 
represent mean + S.E. of means for each condition, respectively. Plasma glucose level was determined in
a Beckman Glucose Analyzer 2 at 20 °C. Rat PP was measured as described under Materials and 
Methods. 
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Fig. 3. Rat-PP release during insulin induced hypoglycemia in normal conscious rats. Graphs how 
mean + S.E.M. of plasma RPP (upper graph) and plasma glucose l vel (lower graph) before and 30 min after 
intravenous (bolus) insulin administration (2 units/kg body weight, n= 15). 
during insulin induced hypoglycemia in normal rats is shown in Fig. 3. Glucose levels 
fell significantly from 107 + 5 to 33 + 2 mg/dl by 30 min after a bolus insulin infusion. 
PP levels rose from 38 + 5 pg/ml to 261 + 34 pg/ml (P < 0.0005) at 30 min. 
Discussion 
Rats and mice are widely used animal models in the study of pathophysiology of
human diabetes mellitus, obesity and autonomic neuropathy, etc. These experiments 
often require an evaluation of endogenous pancreatic polypeptide (PP) secretion. Previ- 
ously, the specific measurement of pM levels of PP in rat and murine plasma was not 
possible. This study validates a specific and sensitive radioimmunoassay (RIA) for 
rat-PP in serum or plasma. The assay is simple, and is easily applicable in glycemic 
studies using rat and mouse models. 
Previously reported RIA for rat-PP in tissues [16], pancreas perfusate [ 17] and serum 
[ 18] often made use of either a rabbit anti-rat PP antibody originally reported by 
Kimmel et al. [ 19] in a 48 h equilibrium incubation with a dextran/charcoal technique 
of separation of bound ~ 25I from free [ 18 ], or c arboxyl-terminal hexapeptide antibodies 
in a 24 h disequilibrium incubation and a 24 h second antibody precipitation [20]. In 
the reports cited, with two exceptions (Refs. 16 and 18), bovine-PP tracer was used. 
While these assay procedure measured levels of PP, assay specificity and sensitivity 
appeared highly compromised. For example, carboxyl-terminal hexapeptide antiserum 
is also capable of cross-reacting with neuro-peptide Y and peptide YY [21,22]. Addi- 
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tionally, rat PP from pancreatic extracts have been shown to cross-react poorly and 
non-specifically with bovine-PP antibody and tracer [3]. The only available report of 
RIA for rat-PP in serum (Miyasaka et al. [ 18]) in which both the anti-rat PP antibody 
and rat-PP tracer were used in the assay achieved sensitivity of 80 pg/ml with a inter 
and intra assay ~o CV of 10 ~o. Detailed characterization f the assay was not presented. 
PP assay sensitivity of 80 pg/ml is incapable of detecting low rat-PP levels under various 
experimental conditions uch as fasting and feeding ad libitum without concentration 
of serum prior to assay. Studies of rodent PP levels are therefore frequently plagued by 
inconsistent values. We have developed a highly reproducible RIA for rat-PP in serum 
that achieves ensitivity of 19 pg/ml (4.5 pM) PP at + 3 S.D. The assay produces no 
cross-reactivity with a variety of hormones and peptides likely to co-circulate inplasma, 
see Table III. The percent intra- and between-assay coefficient of variation are 6.4 ~o 
and 5.9~o, respectively (Table Ia,b). The antibody also cross-reacts well with mouse-PP 
as determined by linear serum dilution curves (data not presented), thus making it useful 
in the measurement of murine-PP. 
The remarkable sensitivity of this assay is due to the antibody's high affinity constant 
and the result of step-wise sequence addition of antibody and labeled ligand, a proce- 
dure termed 'sequential saturation' [23]. The sensitivity of 19 pg/ml at + 3 S.D. is 
particularly desirable when samples volumes available for assay are small, as in the case 
of multiple sampling protocols from rats or mice, and makes possible accurate assess- 
ment of the low fasting concentrations which ranged from 29 pg/ml (6.9 pM) to 45 pg/ml 
(10.7 pM) in normal rats. 
In conclusion, we have developed and characterized a rat-PP assay which is sensitive, 
simple and specific for rat-PP. It is applicable in laboratory studies of normal physiology 
and disease processes to ascertain PPlevels in serum in rodent models and also 
provides a new tool for reliable measurements of rat- and mouse-PP levels as indeces 
of parasympathetic nervous input to the pancreatic islets [24]. 
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